Company profile: Guard Therapeutics
1.1 - Company Overview
Company description
- Provider of drug candidates for oxidative stress and kidney disease, including RMC-035, a biological therapy mimicking human A1M to prevent acute kidney injury during open-heart surgery, kidney transplantation or sepsis, and GTX-peptider, preclinical A1M fragment–mimicking peptides intended for chronic treatment of kidney diseases and self-administration via subcutaneous injection.
Products and services
- GTX-peptider (GTX-peptides): Preclinical drug candidates that mimic fragments of human A1M for chronic kidney disease, enabling self-administration via subcutaneous injection
- RMC-035 (Kidney transplantation): Biological A1M-mimetic drug candidate aimed at preventing acute kidney injury episodes during kidney transplantation procedures
- RMC-035 (Open-heart surgery and sepsis): Biological A1M-mimetic drug candidate aimed at preventing acute kidney injury during open-heart surgery or sepsis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Guard Therapeutics
Allena Pharmaceuticals
HQ: United States
Website
- Description: Provider of non-systemic protein therapeutics to treat metabolic and orphan diseases, engaged in development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allena Pharmaceuticals company profile →
Potrero Medical
HQ: United States
Website
- Description: Provider of predictive health technologies developing smart sensors and AI, including the Accuryn Monitoring System for real-time monitoring of urine output, intra-abdominal pressure, and core body temperature to detect acute kidney injury risk; AccuTab software for visualizing and annotating data; and Accuryn SmartFoley catheters designed to reduce CAUTIs by preventing urine backflow.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Potrero Medical company profile →
Gambro
HQ: Sweden
Website
- Description: Provider of medical technology developing, manufacturing and supplying products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gambro company profile →
Theradial
HQ: France
Website
- Description: Provider of medical devices in France serving health actors in dialysis-nephrology, gastroenterology and onco-hematology. Offers Renoral nutritional supplement for hemodialysis patients; Hemadialyse and MEDWARE software for patient data/records; Théradata CNIL-authorized nephrology-dialysis data repository; InBody S10 and InBody BWA 2.0 bioimpedance analyzers, and partners with the medical and scientific community via clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theradial company profile →
MediBeacon
HQ: United States
Website
- Description: Provider of optical diagnostic solutions for non-invasive organ function measurement, including the Transdermal GFR Measurement System (TGFR) that assesses kidney function via a fluorescent tracer (Lumitrace) detected through the skin, plus TGFR Sensors and Monitors for real-time data. Also offers novel fluorescent tracer agents and highly engineered transdermal sensors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MediBeacon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Guard Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Guard Therapeutics
2.2 - Growth funds investing in similar companies to Guard Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Guard Therapeutics
4.2 - Public trading comparable groups for Guard Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →